Yesterday, Nov. 3, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $9.84 to $10,914,626.52.

Highlighted Stocks Traded by Insiders:

Cara Therapeutics (CARA) - FREE Research Report

Menzaghi Frederique Ph.D., who is VP-Research & Development at Cara Therapeutics, sold 6,000 shares at $14.26 on Nov. 3, 2015. Following this transaction, the VP-Research & Development owned 147,000 shares meaning that the stake was reduced by 3.92% with the 6,000-share transaction.

The shares most recently traded at $15.95, up $1.69, or 10.6% since the insider transaction. Historical insider transactions for Cara Therapeutics go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 6,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 41,524

The average volume for Cara Therapeutics has been 325,500 shares per day over the past 30 days. Cara Therapeutics has a market cap of $422.7 million and is part of the health care sector and drugs industry. Shares are up 53.66% year-to-date as of the close of trading on Tuesday.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Currently, there are 3 analysts who rate Cara Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CARA - FREE

TheStreet Quant Ratings

rates Cara Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full

Cara Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Installed Building Products (IBP) - FREE Research Report

Installed Building Systems, Inc., who is Director at Installed Building Products, bought 50,000 shares at $21.68 on Nov. 3, 2015. Following this transaction, the Director owned 3.5 million shares meaning that the stake was boosted by 1.44% with the 50,000-share transaction.

The shares most recently traded at $22.69, up $1.01, or 4.46% since the insider transaction. Historical insider transactions for Installed Building Products go as follows:

  • 4-Week # shares bought: 5,370
  • 12-Week # shares bought: 5,370
  • 24-Week # shares bought: 5,370

The average volume for Installed Building Products has been 195,100 shares per day over the past 30 days. Installed Building Products has a market cap of $691.6 million and is part of the industrial goods sector and materials & construction industry. Shares are up 29.01% year-to-date as of the close of trading on Tuesday.

Installed Building Products, Inc., together with its wholly owned subsidiaries, primarily engages in the installation of insulation, garage doors, rain gutters, shower doors, closet shelving and mirrors, and other products in the continental United States. The company has a P/E ratio of 441.0. Currently, there are 5 analysts who rate Installed Building Products a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBP - FREE

TheStreet Quant Ratings

rates Installed Building Products as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full

Installed Building Products Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Datalink (DTLK) - FREE Research Report

O Grady Michael Shawn, who is EVP Field Operations at Datalink, sold 10,000 shares at $7.73 on Nov. 3, 2015. Following this transaction, the EVP Field Operations owned 68,900 shares meaning that the stake was reduced by 12.67% with the 10,000-share transaction.

The shares most recently traded at $7.90, up $0.17, or 2.19% since the insider transaction. Historical insider transactions for Datalink go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 42,000

The average volume for Datalink has been 146,500 shares per day over the past 30 days. Datalink has a market cap of $181.7 million and is part of the technology sector and computer hardware industry. Shares are down 39.07% year-to-date as of the close of trading on Tuesday.

Datalink Corporation provides data center services and solutions. The company has a P/E ratio of 19.0. Currently, there are 2 analysts who rate Datalink a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DTLK - FREE

TheStreet Quant Ratings

rates Datalink as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

Datalink Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.